These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7600680)

  • 1. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics.
    Nowak I; Shaw LM
    Clin Chem; 1995 Jul; 41(7):1011-7. PubMed ID: 7600680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IMP-dehydrogenase inhibition in human lymphocytes and lymphoblasts by mycophenolic acid and mycophenolic acid glucuronide.
    Griesmacher A; Weigel G; Seebacher G; Müller MM
    Clin Chem; 1997 Dec; 43(12):2312-7. PubMed ID: 9439448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of mycophenolic acid glucuronide on inosine monophosphate dehydrogenase activity.
    Nowak I; Shaw LM
    Ther Drug Monit; 1997 Jun; 19(3):358-60. PubMed ID: 9200779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid.
    Iwasaki K; Miyazaki Y; Teramura Y; Kawamura A; Tozuka Z; Hata T; Undre N
    Res Commun Mol Pathol Pharmacol; 1996 Dec; 94(3):251-7. PubMed ID: 9029671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of mycophenolic acid alone and in combination with its metabolite mycophenolic acid glucuronide on rat embryos in vitro.
    Schmidt F; Eckardt K; Shakibaei M; Glander P; Stahlmann R
    Arch Toxicol; 2013 Feb; 87(2):361-70. PubMed ID: 22914985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro influence of fatty acids and bilirubin on binding of mycophenolic acid to human serum albumin.
    Vial Y; Tod M; Hornecker M; Urien S; Conti F; Dauphin A; Calmus Y; Blanchet B
    J Pharm Biomed Anal; 2011 Feb; 54(3):607-9. PubMed ID: 20965681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of inosine monophosphate dehydrogenase activity in human CD4+ cells isolated from whole blood during mycophenolic acid therapy.
    Vethe NT; Bergan S
    Ther Drug Monit; 2006 Oct; 28(5):608-13. PubMed ID: 17038874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spectroscopy study and co-administration effect on the interaction of mycophenolic acid and human serum albumin.
    Ma X; Yan J; Wang Q; Wu D; Li H
    Int J Biol Macromol; 2015; 77():280-6. PubMed ID: 25841376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients.
    Mino Y; Naito T; Otsuka A; Ozono S; Kagawa Y; Kawakami J
    Clin Chim Acta; 2009 Nov; 409(1-2):56-61. PubMed ID: 19723513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure.
    Kaplan B; Gruber SA; Nallamathou R; Katz SM; Shaw LM
    Transplantation; 1998 Apr; 65(8):1127-9. PubMed ID: 9583876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycophenolic acid monitoring in HTX patients: a preliminary report.
    Müller MM; Vogl M; Griesmacher A
    Therapie; 1997; 52(4):341-4. PubMed ID: 9437889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.
    Atcheson BA; Taylor PJ; Mudge DW; Johnson DW; Hawley CM; Campbell SB; Isbel NM; Pillans PI; Tett SE
    Br J Clin Pharmacol; 2005 Mar; 59(3):271-80. PubMed ID: 15752372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mycophenolate acyl-glucuronide on human recombinant type 2 inosine monophosphate dehydrogenase.
    Gensburger O; Picard N; Marquet P
    Clin Chem; 2009 May; 55(5):986-93. PubMed ID: 19299544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals.
    Vethe NT; Bremer S; Rootwelt H; Bergan S
    Ther Drug Monit; 2008 Dec; 30(6):647-55. PubMed ID: 18806697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combined photophysical and computational study on the binding of mycophenolate mofetil and its major metabolite to transport proteins.
    Vendrell-Criado V; González-Bello C; Miranda MA; Jiménez MC
    Spectrochim Acta A Mol Biomol Spectrosc; 2018 Jun; 199():308-314. PubMed ID: 29627615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate pharmacokinetics and inosine monophosphate dehydrogenase activity in liver transplant recipients with an emphasis on therapeutic drug monitoring.
    Reine PA; Vethe NT; Kongsgaard UE; Andersen AM; Line PD; Ali AM; Bergan S
    Scand J Clin Lab Invest; 2013 Mar; 73(2):117-24. PubMed ID: 23281843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics of mycophenolate mofetil.
    Bullingham RE; Nicholls AJ; Kamm BR
    Clin Pharmacokinet; 1998 Jun; 34(6):429-55. PubMed ID: 9646007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus.
    Mino Y; Naito T; Shimoyama K; Ogawa N; Kawakami J
    Ann Clin Biochem; 2017 Jul; 54(4):490-494. PubMed ID: 27538768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
    Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
    Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.